SEC Form 4 · accession 0001193125-26-387934
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jennifer Fulk
Officer — Chief Financial Officer
Period of report
Sep 8, 2026
Accepted (ET)
Sep 10, 2026 · 4:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001422143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF1 | $12.52 | Sep 8, 2026 | A | 450,000 | A | — | Sep 7, 2036 | Common Stock | 450,000 | 450,000 | D |
Explanation of responses
- F11/4th of the shares vest on the one year anniversary of the vesting commencement date, and 1/48th of the shares vest in 36 monthly installments thereafter.